- Home
- OGN vs ADMA Comparison
OGN vs ADMA Comparison
Compare OGN & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGN
- ADMA
- Stock Information
- Founded
- OGN 1923
- ADMA 2004
- Country
- OGN United States
- ADMA United States
- Employees
- OGN N/A
- ADMA N/A
- Industry
- OGN Biotechnology: Pharmaceutical Preparations
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OGN Health Care
- ADMA Health Care
- Exchange
- OGN Nasdaq
- ADMA Nasdaq
- Market Cap
- OGN 4.0B
- ADMA 4.1B
- IPO Year
- OGN N/A
- ADMA N/A
- Fundamental
- Price
- OGN $15.89
- ADMA $16.16
- Analyst Decision
- OGN Hold
- ADMA Strong Buy
- Analyst Count
- OGN 3
- ADMA 4
- Target Price
- OGN $21.33
- ADMA $21.25
- AVG Volume (30 Days)
- OGN 4.3M
- ADMA 2.4M
- Earning Date
- OGN 02-13-2025
- ADMA 02-26-2025
- Dividend Yield
- OGN 7.06%
- ADMA N/A
- EPS Growth
- OGN 120.97
- ADMA N/A
- EPS
- OGN 5.04
- ADMA 0.28
- Revenue
- OGN $6,409,000,000.00
- ADMA $382,809,000.00
- Revenue This Year
- OGN $3.29
- ADMA $66.90
- Revenue Next Year
- OGN $1.93
- ADMA $13.76
- P/E Ratio
- OGN $3.15
- ADMA $57.65
- Revenue Growth
- OGN 4.21
- ADMA 63.39
- 52 Week Low
- OGN $13.87
- ADMA $5.02
- 52 Week High
- OGN $23.10
- ADMA $23.64
- Technical
- Relative Strength Index (RSI)
- OGN 55.80
- ADMA 37.26
- Support Level
- OGN $15.52
- ADMA $15.92
- Resistance Level
- OGN $16.23
- ADMA $17.32
- Average True Range (ATR)
- OGN 0.53
- ADMA 0.87
- MACD
- OGN 0.10
- ADMA -0.15
- Stochastic Oscillator
- OGN 79.22
- ADMA 7.21
About OGN Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.